Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

Abstract Background Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of...

Full description

Bibliographic Details
Main Authors: Jordi Real, Bogdan Vlacho, Emilio Ortega, Joan Antoni Vallés, Manel Mata-Cases, Esmeralda Castelblanco, Eric T. Wittbrodt, Peter Fenici, Mikhail Kosiborod, Dídac Mauricio, Josep Franch-Nadal
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2i
Heart failure
All-cause mortality
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1186/s12933-021-01323-5

Internet

https://doi.org/10.1186/s12933-021-01323-5

Similar Items